Elicio Therapeutics (ELTX) KOL event summary

Introduction and agenda

• The event focused on clinical and translational observations and the development path for ELI-002/ELI-002 7P in metastatic KRAS-mutated pancreatic ductal adenocarcinoma (PDAC), with presentations from expert oncologists and a live Q&A session.

• The agenda included review of historical response rates, clinical case presentations, translational data, Phase 1 strategy, and plans for prospective studies.

KOL background and credentials

• Presenters included Dr. Peter Hosein (Professor, University of Miami), Dr. Zev Wainberg (Professor, UCLA), and Dr. Christopher Haqq (EVP, Head of R&D, CMO).

Market insights and analysis

• Complete and durable responses in metastatic PDAC are extremely rare, with historical CR rates of 0–8% across standard and experimental regimens.

• Immunotherapy, particularly checkpoint inhibitors and combinations, has shown minimal efficacy in pancreatic cancer, with CR rates typically below 6%.